Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
DNTHthis companyDianthus Therapeutics, Inc.	$86.46	-9.81×	3.16×	764.98×	-9.31×	-101.9%	100.0%	-8739.3%	-7973.3%	-32.9%	-35.5%	-8.3%	0×	0.31×	0×	13.32×	0.0%	1	67.2	2	C
ALMSAlumis Inc.	$6.03	-4.21×	27.54×	345.07×	-33.2×	-85.0%	85.5%	-1776.3%	-1011.7%	-80.8%	-120.2%	-4.5%	0.12×	0.21×	0×	4.34×	0.0%	2	0.06	1	C-
ANABAnaptysBio, Inc.	$46.78	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
ARTVArtiva Biotherapeutics, Inc.	$4.22	-1.25×	0.95×	0×	-1.1×	-84.3%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-75.7%	0.1×	0.19×	0×	8.61×	0.0%	1	4.66	2	C+
CNTBConnect Biopharma Holdings Limited	$0.75	-2.82×	3.74×	2,452.52×	-2.19×	-15.8%	100.0%	-90740.6%	-86687.5%	-132.2%	-135.7%	-32.9%	0.02×	0.69×	0×	3.74×	0.0%	2	-15.61	2	C+
IMVTImmunovant, Inc.	$33.48	-8.97×	5.31×	0×	-7.19×	-83.0%	0.0%	0.0%	0.0%	-59.3%	-62.5%	-9.0%	0×	1.79×	0×	9.09×	0.0%	3	26.71	1	D+
Peer median	—	-4.21×	5.31×	3.83×	-2.19×	-84.3%	85.5%	0.0%	-5.6%	-76.3%	-74.9%	-9.0%	0.1×	0.21×	0×	8.61×	0.0%	2	2.21	2	—